ストックスクリーナーアプリを入手
35.81
2.93%
-1.08
前日終値:
$36.89
開ける：
$36.66
24時間の取引高:
231.29K
Relative Volume:
0.57
時価総額：
$1.92B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-8.41%
1か月 パフォーマンス:
-0.20%
6か月 パフォーマンス:
+269.94%
1年 パフォーマンス:
+277.74%
1日の値動き範囲:
$34.61
$38.52
1週間の範囲:
$31.48
$41.10
52週間の値動き範囲:
$5.83
$41.50
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
35.81 | 1.98B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
Zenas BioPharma approves 2026 inducement plan - MSN
H.C. Wainwright reiterates Buy rating on Zenas Biopharma stock amid competitor setback - Investing.com Canada
Zenas BioPharma (NASDAQ:ZBIO) Trading 6.7% HigherTime to Buy? - MarketBeat
Zenas BioPharma Shares Surge Amid Promising Drug Trials - TipRanks
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential - TipRanks
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside - TipRanks
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod - Indian Pharma Post
Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Yahoo Finance
Zenas BioPharma (ZBIO): Reassessing a Rich Valuation After Positive Orelabrutinib Lupus Trial Milestones - Sahm
Zenas BioPharma Approves 2026 Inducement Plan - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 9.9%Should You Sell? - MarketBeat
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How - GuruFocus
InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib - TipRanks
Innocare Pharma announces achievement of primary endpoint in phase 2b study of orelabrutinib - marketscreener.com
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - The Manila Times
InnoCare Pharma Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib - marketscreener.com
Zenas Prepares For INDIGO Phase 3 Readout—Reinstating Buy Rating (ZBIO) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
IgG4-related Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht - The Globe and Mail
Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Hits New 52-Week HighHere's Why - MarketBeat
Zenas Biopharma stock hits all-time high at 41.37 USD By Investing.com - Investing.com Canada
Zenas Biopharma stock hits all-time high at 41.37 USD - Investing.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Would You Still Hold Zenas BioPharma Stock If It Fell 30%? - Trefis
Taking Stock of Zenas BioPharma (ZBIO) Valuation After Royalty Pharma Financing Boost - Sahm
2025-12-04 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse
Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation - Insider Monkey
Is Zenas BioPharma Inc. stock trading near support levelsQuarterly Trade Report & Low Risk Entry Point Guides - Newser
Can Zenas BioPharma Stock Hold Up When Markets Turn? - Trefis
Did You Lose Money on Zenas BioPharma, Inc. (ZBIO)? Levi & Korsinsky Urges Investors to Act Before June 16, 2025 - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO)Contact Levi & Korsinsky Before June 16, 2025 - The National Law Review
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
EV Market: How interest rate cuts could boost Zenas BioPharma Inc. stockWeekly Loss Report & Reliable Breakout Stock Forecasts - BỘ NỘI VỤ
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 3.5%Here's What Happened - MarketBeat
Update Report: Can Zenas BioPharma Inc. stock reach $100 price targetJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - moha.gov.vn
Zenas BioPharma Reports Q3 2025 Financial Results - MSN
How interest rate cuts could boost Zenas BioPharma Inc. stockWeekly Trade Summary & Real-Time Market Sentiment Reports - BỘ NỘI VỤ
Evercore ISI Initiates Coverage on Zenas BioPharma (NASDAQ:ZBIO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Now Covered by Evercore ISI - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Reaches New 52-Week HighShould You Buy? - MarketBeat
Can Zenas BioPharma's (ZBIO) Improving Loss Per Share Shift Investor Confidence in Its Long-Term Story? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Connect - ACCESS Newswire
Zenas Biopharma stock hits all-time high at 38.92 USD By Investing.com - Investing.com Australia
Zenas Biopharma stock hits all-time high at 38.92 USD - Investing.com
IgG4-related disease Market Size was USD 170 million in 2024, - openPR.com
Zenas Biopharma Inc (ZBIO) 財務データ
Zenas Biopharma Inc (ZBIO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.18%
0.62%
大文字化:
|
ボリューム (24 時間):